Elekta (OTCMKTS:EKTAY) Stock Rating Upgraded by Zacks Research

Elekta (OTCMKTS:EKTAY) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Elekta Trading Up 0.5%

Shares of OTCMKTS:EKTAY opened at $4.99 on Tuesday. The company has a market capitalization of $1.84 billion, a PE ratio of -31.16 and a beta of 1.01. The company has a current ratio of 0.87, a quick ratio of 0.68 and a debt-to-equity ratio of 0.47. Elekta has a 12-month low of $4.35 and a 12-month high of $6.93. The business’s fifty day simple moving average is $5.32 and its 200-day simple moving average is $5.86.

Elekta (OTCMKTS:EKTAY) last issued its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%.The firm had revenue of $521.00 million during the quarter. As a group, equities research analysts predict that Elekta will post 0.43 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.